文献速递艾滋病与性传播感染

早期启动抗逆转录病毒治疗与HIV感染者癌症风险

Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus.
PubMed 文献 · Clin Infect Dis · 2021-01-01

研究基于北美22个队列1996–2014年无AIDS、未治疗HIV感染者,比较基线后6个月内早期启动抗逆转录病毒治疗(ART)与延迟启动对癌症风险的影响。早期ART与任何癌症、AIDS定义性癌症、病毒相关癌症、卡波西肉瘤及非霍奇金淋巴瘤风险降低相关,但未见于无已知病毒病因的非AIDS定义性癌症。

要点

  • 早期启动ART可降低HIV感染者病毒相关癌症风险
  • 早期ART对AIDS定义性癌症和非霍奇金淋巴瘤保护作用明显
  • 对无已知病毒病因的非AIDS定义性癌症未见保护作用

核心结论

  • 早期启动ART可能降低HIV感染者病毒相关癌症负担,但不降低无已知或疑似病毒病因的非AIDS定义性癌症风险。

研究设计与样本

  • 研究为多队列观察性分析,纳入北美AIDS队列研究协作(NA-ACCORD)22个队列1996–2014年无AIDS且未治疗HIV感染者。
  • 采用边际结构模型与逆概率加权校正时间依赖混杂和信息性右删失。

主要发现

  • 早期ART与任何癌症风险降低相关(调整HR 0.57;95%CI .37-.86)。
  • 早期ART与AIDS定义性癌症风险降低相关(HR 0.23;95%CI .11-.49)。
  • 早期ART与任何病毒相关癌症风险降低相关(HR 0.30;95%CI .16-.54)。
  • 早期ART与卡波西肉瘤风险降低相关(HR 0.25;95%CI .10-.61),与非霍奇金淋巴瘤风险降低相关(HR 0.22;95%CI .06-.73)。
  • 随访至15年时,早期ART组病毒相关非AIDS定义性癌症风险较低(0.6% vs 2.3%;调整风险差-1.6;95%CI -2.8,-.5)。

临床怎么用

  • 对CD4 350–500 cells/µL的未治疗HIV感染者,应尽早启动ART以降低病毒相关癌症风险。
  • 癌症预防咨询可强调早期ART对AIDS定义性癌症和病毒相关癌症的潜在获益。

局限性

  • 研究为观察性队列分析,虽用边际结构模型校正混杂,仍不能完全排除残余混杂。
  • 结论主要适用于CD4 350–500 cells/µL且无AIDS的HIV感染者,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persons living with human immunodeficiency virus (HIV; PLWH) experience a high burden of cancer. It remains unknown which cancer types are reduced in PLWH with earlier initiation of antiretroviral therapy (ART). METHODS: We evaluated AIDS-free, ART-naive PLWH during 1996-2014 from 22 cohorts participating in the North American AIDS Cohort Collaboration on Research and Design. PLWH were followed from first observed CD4 of 350-500 cells/µL (baseline) until incident cancer, death, lost-to-follow-up, or December 2014. Outcomes included 6 cancer groups and 5 individual cancers that were confirmed by chart review or cancer registry linkage. We evaluated the effect of earlier (in the first 6 months after baseline) versus deferred ART initiation on cancer risk. Marginal structural models were used with inverse probability weighting to account for time-dependent confounding and informative right-censoring, with weights informed by subject's age, sex, cohort, baseline year, race/ethnicity, HIV transmission risk, smoking, viral hepatitis, CD4, and AIDS diagnoses. RESULTS: Protective results for earlier ART were found for any cancer (adjusted hazard ratio [HR] 0.57; 95% confidence interval [CI], .37-.86), AIDS-defining cancers (HR 0.23; 95% CI, .11-.49), any virus-related cancer (HR 0.30; 95% CI, .16-.54), Kaposi sarcoma (HR 0.25; 95% CI, .10-.61), and non-Hodgkin lymphoma (HR 0.22; 95% CI, .06-.73). By 15 years, there was also an observed reduced risk with earlier ART for virus-related NADCs (0.6% vs 2.3%; adjusted risk difference -1.6; 95% CI, -2.8, -.5). CONCLUSIONS: Earlier ART initiation has potential to reduce the burden of virus-related cancers in PLWH but not non-AIDS-defining cancers (NADCs) without known or suspected viral etiology.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Silverberg MJ, Leyden W, Hernández-Ramírez RU, et al. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021. PMID: 32785640. doi:10.1093/cid/ciaa1046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。